UNSPSC 51282905: Besifloxacin

This classification denotes a quinolone antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BFE2NBZ7NX. European Medicines Agency schedules Besifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33064. Besifloxacin generally arises in the molecular formula C19H21CLFN3O3. The term BESIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60.) Most nations schedule besifloxacin under HS 29334900 and SITC 51575.

As of Q4 2014, BESIFLOXACIN remains the US FDA Preferred Term for this commodity. Besifloxacin bears US NLM identifiers UMLS ID C2351042 and NCI Concept Code C83553. SMILES: C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.

UNSPSC 51282905 Besifloxacin, a Commodity code, does not align with the recent state and local opportunities posted under this classification. The code nominally represents a specific ophthalmic antibiotic; however, the recent solicitations tagged to this code solicited naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products. These procurement activities span public health emergency response, pharmacy benefit management, emergency medical services, and bulk pharmaceutical distribution—none of which correspond to besifloxacin or its intended use. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (MMCAP). The geographic spread includes Florida, Texas, and Minnesota, with MMCAP's membership extending to Oregon and other participating jurisdictions.

The code shows a fundamental mismatch between its pharmaceutical taxonomy placement and actual state and local procurement activity. The tagged opportunities reflect broad-based pharmaceutical procurement—including naloxone IFBs, pharmacy benefit RFIs, emergency medical supplies ITBs, and cooperative multi-source drug RFPs—rather than procurement of besifloxacin specifically. This misalignment suggests either a cataloging error in how opportunities were coded or a disconnect between the code's narrow pharmaceutical scope and the jurisdictions' use of it to solicit related but distinct products and services. Business development professionals evaluating this code should verify with issuing bodies whether besifloxacin procurement occurs under different codes, or whether the state and local market for this specific ophthalmic antibiotic operates outside standard UNSPSC classification frameworks.